This week in therapeutics




Licensing status

Publication and contact information

Endocrine/metabolic disease


K(lysine) acetyltransferase 2B (KAT2B; PCAF)

Mouse studies suggest antagonizing KAT2B could help lower glucose levels and help treat type 2 diabetes. In fasting mice, liver-specific RNAi knockdown of Kat2b prevented histone H3K9 acetylation and expression of gluconeogenic genes and decreased circulating glucose levels compared with no knockdown. In insulin-resistant mouse models of obesity and diabetes, anacardic acid, a natural product that inhibits KAT2B, decreased gluconeogenic gene expression compared with a nonspecific compound. Next steps could include developing a KAT2B antagonist.

SciBX 6(40); doi:10.1038/scibx.2013.1127
Published online Oct. 17, 2013

Patent and licensing status unavailable

Ravnskjaer, K. et al. J. Clin. Invest.; published online Sept. 24, 2013;
Contact: Marc Montminy, Salk Institute for Biological Studies, La Jolla, Calif.